ESMO-Magnitude of Clinical Benefit Scale version 1.1
Top Cited Papers
- 1 October 2017
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 28 (10), 2340-2366
- https://doi.org/10.1093/annonc/mdx310
Abstract
The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.0 (v1.0) was published in May 2015 and was the first version of a validated and reproducible tool to assess the magnitude of clinical benefit from new cancer therapies. The ESMO-MCBS was designed to be a dynamic tool with planned revisions and updates based upon recognition of expanding needs and shortcomings identified since the last review.The revision process for the ESMO-MCBS incorporates a nine-step process: Careful review of critiques and suggestions, and identification of problems in the application of v1.0; Identification of shortcomings for revision in the upcoming version; Proposal and evaluation of solutions to address identified shortcomings; Field testing of solutions; Preparation of a near-final revised version for peer review for reasonableness by members of the ESMO Faculty and Guidelines Committee; Amendments based on peer review for reasonableness; Near-final review by members of the ESMO-MCBS Working Group and the ESMO Executive Board; Final amendments; Final review and approval by members of the ESMO-MCBS Working Group and the ESMO Executive Board.Twelve issues for revision or amendment were proposed for consideration; proposed amendments were formulated for eight identified shortcomings. The proposed amendments are classified as either structural, technical, immunotherapy triggered or nuanced. All amendments were field tested in a wide range of studies comparing scores generated with ESMO-MCBS v1.0 and version 1.1 (v1.1).ESMO-MCBS v1.1 incorporates 10 revisions and will allow for scoring of single-arm studies. Scoring remains very stable; revisions in v1.1 alter the scores of only 12 out of 118 comparative studies and facilitate scoring for single-arm studies.Keywords
Funding Information
- ESMO
This publication has 47 references indexed in Scilit:
- Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trialThe Lancet Oncology, 2013
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian CancerThe New England Journal of Medicine, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerThe New England Journal of Medicine, 2012
- A Phase 3 Trial of Bevacizumab in Ovarian CancerThe New England Journal of Medicine, 2011
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaThe New England Journal of Medicine, 2011
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous SclerosisThe New England Journal of Medicine, 2010
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2010
- Process Is the PointAmerican Journal of Public Health, 2008
- Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studiesJournal of the American Academy of Dermatology, 2004